Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506449 · ClinicalTrials.gov registry record · NA
The RECOVER IV Trial
A NA study, sponsored by Abiomed.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05506449 is a NA study that was terminated before completion, run by Abiomed. The registered enrollment target is 4 participants.
The verdict
NCT05506449, a NA study, was terminated before completion, sponsored by Abiomed.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction (STEMI)-Cardiogenic Shock (CS) improves survival and functional outcomes compared to a non-Impella-based treatment strategy.
Interventions
- OTHER Standard of Care
- DEVICE Impella CP®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-10-28 |
| Est. Completion | 2024-12-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05506449
The ClinicalTrials.gov registry entry for NCT05506449 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abiomed, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05506449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05506449 about?
NCT05506449 is a clinical study titled "The RECOVER IV Trial". The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction (STEMI)-Cardiogenic Shock (CS) improves survival and functional outcomes...
What is the current status of trial NCT05506449?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2023-10-28. Estimated completion is 2024-12-06.
What interventions are being tested in trial NCT05506449?
The interventions under investigation include: Standard of Care (OTHER), Impella CP® (DEVICE).
Who is sponsoring clinical trial NCT05506449?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.